Home › Calculator › LGNZZ Dividend Calculator 2026
LGNZZ Dividend DRIP Calculator 2026
3333.33% YieldHealthcareLigand Pharmaceuticals, Inc. · OTC
Price: $0.06 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When LGNZZ pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your LGNZZ snowball 📈
$10,000 in LGNZZ → $9837447274.18M in 10 years · $687,719,344,740,546.40/month
About Ligand Pharmaceuticals, Inc. (LGNZZ) — Dividend Analysis 2026
Ligand Pharmaceuticals, Inc. operates as a global biopharmaceutical firm dedicated to advancing and licensing pharmaceutical assets. The company's portfolio features a diverse array of therapies addressing critical health conditions. Key products include Kyprolis and Evomela, both indicated for multiple myeloma; Rylaze, an effective treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in pediatric and adult populations; and Filspari, a dual antagonist in development for rare kidney diseases and immunoglobulin A nephropathy. Ligand also provides Teriparatide injections for osteoporosis, alongside vaccines such as Vaxneuvance, designed to prevent invasive disease caused by streptococcus pneumoniae serotypes, and Pneumosil, a pneumococcal conjugate vaccine for children. Their offerings extend to TZIELD, a CD3-directed antibody aimed at delaying the onset of Stage 3 Type 1 diabetes in adults and children aged 8 and older diagnosed with Stage 2 T1D. A core technological strength for Ligand is its Captisol platform, which enhances drug formulations. This is utilized in products like Nexterone (an amiodarone formulation), Zulresso (for postpartum depression), Veklury (an antiviral for moderate to severe COVID-19), and Noxafil-IV. Additional treatments in their pipeline target post-menopausal symptoms (Duavee), autoimmune diseases (Exemptia), breast cancer (Vivitra), and a variety of other indications with Bryxta and Zybev. Beyond its own product advancements, Ligand cultivates strategic partnerships and licensing agreements with prominent pharmaceutical entities such as Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. The company also generates revenue by selling its Captisol materials. Established in 1987, Ligand Pharmaceuticals is headquartered in Jupiter, Florida.
Compare LGNZZ with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full LGNZZ DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LGNZZ position with:
🌍 LGNZZ Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold LGNZZ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3333.33% | 3330.53% | $333,333 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2833.33% | 2830.53% | $283,333 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2666.66% | 2663.86% | $266,666 / yr |
| 🇬🇧 UK ISA | 0% | 3333.33% | 3330.53% | $333,333 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3041.66% | 3038.86% | $304,166 / yr |
| 🇨🇦 TFSA | 0% | 3333.33% | 3330.53% | $333,333 / yr |
| 🇨🇦 CA Taxable | 25% | 2500.00% | 2497.20% | $250,000 / yr |
| 🇦🇺 Super (pension) | 15% | 2833.33% | 2830.53% | $283,333 / yr |
| 🇦🇺 AU Taxable | 30% | 2333.33% | 2330.53% | $233,333 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2454.16% | 2451.36% | $245,416 / yr |
| 🇫🇷 FR Taxable | 30% | 2333.33% | 2330.53% | $233,333 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 LGNZZ Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 LGNZZ Dividend Payment Schedule
LGNZZ pays quarterly — 4 times per year. Next ex-div: TBD.
📊 LGNZZ vs Healthcare Benchmarks
How LGNZZ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LGNZZ sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ LGNZZ Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| F-InKind | 2024-01-02 | 2,917 | $72.31 | $210.9K | ||
| J-Other | 2023-12-29 | 179 | $60.71 | $10.9K | ||
| F-InKind | 2023-12-05 | 1,269 | $59.61 | $75.6K | ||
| F-InKind | 2023-12-05 | 1,984 | $59.61 | $118.3K | ||
| F-InKind | 2023-10-01 | 346 | $59.92 | $20.7K | ||
| A-Award | 2023-09-22 | 11,345 | $59.08 | $670.3K | ||
| A-Award | 2023-09-22 | 2,285 | — | — | ||
| Buy | 2023-09-22 | 4,000 | $59.38 | $237.5K | ||
| F-InKind | 2023-08-10 | 897 | $68.73 | $61.7K | ||
| J-Other | 2023-06-30 | 376 | $56.78 | $21.3K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LGNZZ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ligand Pharmaceuticals, Inc. (LGNZZ) is currently trading at $0.06, trading near its 52-week low. The current dividend yield is 3333.33% based on an annual payout of $2.00 per share.
LGNZZ (Ligand Pharmaceuticals, Inc.) — 3333.33% Dividend Yield Analysis
Ligand Pharmaceuticals, Inc. (LGNZZ) is a healthcare stock currently trading at $0.06 with a dividend yield of 3333.33%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (3333.33%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest LGNZZ News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.